Melanoma Clinical Trial

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Summary

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must have either metastatic melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with surgery no later than 12 weeks before the start of treatment and confirmed free of disease
Must have a low level of disability and cancer that is considered advanced for metastatic melanoma and at risk for becoming advanced (intermediate) or advanced for resected melanoma

Exclusion Criteria:

Must not have any brain cancer/disease treated with radiation, any cancer in the eyes or mucous membranes (cells that cover inside surface of parts of the body and keep it moist), any autoimmune disease, or any condition that is being treated with steroids for inflammation (corticosteroids) or medication to decrease the body's immune system response (immunosuppressive drugs)

Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

100

Study ID:

NCT06101134

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 35 Locations for this study

See Locations Near You

Alaska Oncology & Hematology, LLC
Anchorage Alaska, 99508, United States More Info
Steven Liu, Site 0007
Contact
907-257-9851
Mayo Clinic Hospital - Phoenix
Phoenix Arizona, 85054, United States More Info
Mahesh Seetharam, Site 0013
Contact
602-277-4868
University of California, San Francisco, Medical Center at Mount Zion
San Francisco California, 94115, United States More Info
Adil Daud, Site 0010
Contact
415-476-7710
Local Institution - 0034
Atlanta Georgia, 30342, United States More Info
Site 0034
Contact
Saint Elizabeth Healthcare
Edgewood Kentucky, 41017, United States More Info
Daniel Flora, Site 0032
Contact
859-301-4000
University of New Mexico Cancer Center
Albuquerque New Mexico, 87106, United States More Info
Moises Harari-Turquie, Site 0028
Contact
505-570-5835
Icahn School of Medicine at Mount Sinai (ISMMS) - The Derald H. Ruttenberg Treatment Center
New York New York, 10029, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States More Info
Kelly Paulson, Site 0030
Contact
425-673-8300
Local Institution - 0024
Cipolletti R, 8324, Argentina
Local Institution - 0002
Viedma R, R8500, Argentina
Local Institution - 0001
Rosario S, 2000, Argentina
Local Institution - 0015
Las Condes Santiago, 83310, Chile More Info
Site 0015
Contact
Local Institution - 0005
Concepcion , 40701, Chile More Info
Site 0005
Contact
Local Institution - 0016
Las Condes , 75500, Chile More Info
Site 0016
Contact
Bioclinic of Thessaloniki
Thessaloniki B, 546 2, Greece More Info
Ioannis Boukovinas, Site 0019
Contact
306944189715
Local Institution - 0014
Athens I, 115 2, Greece More Info
Site 0014
Contact
Local Institution - 0031
Kifisia I, 145 6, Greece
Athens Medical Center
Marousi I, 151 2, Greece More Info
Apostolos Laskarakis, Site 0029
Contact
+302104809625
Metropolitan General Hospital
Holargos, Athens , 155 6, Greece More Info
Theofanis Floros, Site 0023
Contact
+302106502542
Metropolitan Hospital, Department of Oncology
Peiraias , 185 4, Greece More Info
Dimitrios Bafaloukos, Site 0008
Contact
306944534944
Local Institution - 0033
Thessaloniki , 564 2, Greece More Info
Site 0033
Contact
ASST Papa Giovanni XXIII
Bergamo BG, 24127, Italy More Info
Barbara Merelli, Site 0017
Contact
390352673694
Local Institution - 0035
Meldola FC, 47014, Italy More Info
Site 0035
Contact
Local Institution - 0018
Milan MI, 20141, Italy More Info
Site 0018
Contact
Local Institution - 0012
Padova PD, 35128, Italy More Info
Site 0012
Contact
Istituto Nazionale Tumori Regina Elena
Roma RM, 00144, Italy More Info
Virginia Ferraresi, Site 0021
Contact
+390652666773
Local Institution - 0004
Torino TO, 10126, Italy More Info
Site 0004
Contact
Local Institution - 0026
Napoli , 80130, Italy More Info
Site 0026
Contact
Hospital de la Santa Creu i Sant Pau
Barcelona B, 08025, Spain More Info
Andres Barba Joaquin, Site 0011
Contact
34935565651
Local Institution - 0022
Barcelona B, 08908, Spain More Info
Site 0022
Contact
Hospital Universitario Virgen Arrixaca
Cartagena MU, 30120, Spain More Info
Pablo Cerezuela Fuentes, Site 0009
Contact
+34968506666
Local Institution - 0020
Badalona , 08916, Spain More Info
Site 0020
Contact
Local Institution - 0027
Cantabria , 39008, Spain More Info
Site 0027
Contact
Local Institution - 0003
San Pedro Alcántara, Málaga , 10002, Spain More Info
Site 0003
Contact
Hospital Universitario Virgen del Rocío
Sevilla , 41013, Spain More Info
Maria Pilar Sancho Marquez, Site 0006
Contact
+34955013068

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

100

Study ID:

NCT06101134

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.